Novartis’s Experimental Drug Shrinks Hodgkin’s Lymphoma Tumors

Novartis AG said an experimental drug shrank tumors in 74 percent of patients with Hodgkin’s lymphoma and stabilized the cancer in 82 percent after 9.6 months.

The medicine, called LBH589, provoked a response in 27 percent of patients, the Basel, Switzerland-based company said today in a statement. The mid-stage study, funded by Novartis, followed 129 patients who had received between two and seven prior treatments for Hodgkin’s lymphoma, a cancer of cells that are part of the body’s immune system.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.